WO2013171764A3 - Ophthalmic formulations - Google Patents

Ophthalmic formulations Download PDF

Info

Publication number
WO2013171764A3
WO2013171764A3 PCT/IN2013/000283 IN2013000283W WO2013171764A3 WO 2013171764 A3 WO2013171764 A3 WO 2013171764A3 IN 2013000283 W IN2013000283 W IN 2013000283W WO 2013171764 A3 WO2013171764 A3 WO 2013171764A3
Authority
WO
WIPO (PCT)
Prior art keywords
ophthalmic formulations
relates
present
formulations
fiber based
Prior art date
Application number
PCT/IN2013/000283
Other languages
French (fr)
Other versions
WO2013171764A2 (en
Inventor
Pratibha Sudhir Pilgaonkar
Maharukh Tehmasp Rustomjee
Anilkumar Surendrakumar Gandhi
Original Assignee
Rubicon Research Private Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rubicon Research Private Limited filed Critical Rubicon Research Private Limited
Publication of WO2013171764A2 publication Critical patent/WO2013171764A2/en
Publication of WO2013171764A3 publication Critical patent/WO2013171764A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/08—Mydriatics or cycloplegics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Botany (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to ophthalmic formulations comprising fenugreek fiber based excipient. Particularly the present invention relates to ophthalmic formulations suitable for drug delivery and placebo ocular formulations comprising fenugreek fiber based excipient.
PCT/IN2013/000283 2012-04-30 2013-04-29 Ophthalmic formulations WO2013171764A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1350/MUM/2012 2012-04-30
IN1350MU2012 2012-04-30

Publications (2)

Publication Number Publication Date
WO2013171764A2 WO2013171764A2 (en) 2013-11-21
WO2013171764A3 true WO2013171764A3 (en) 2014-01-23

Family

ID=49584410

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2013/000283 WO2013171764A2 (en) 2012-04-30 2013-04-29 Ophthalmic formulations

Country Status (1)

Country Link
WO (1) WO2013171764A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ2014451A3 (en) 2014-06-30 2016-01-13 Contipro Pharma A.S. Antitumor composition based on hyaluronic acid and inorganic nanoparticles, process of its preparation and use
CZ309295B6 (en) 2015-03-09 2022-08-10 Contipro A.S. Self-supporting, biodegradable film based on hydrophobized hyaluronic acid, method of its preparation and use
CZ2015398A3 (en) 2015-06-15 2017-02-08 Contipro A.S. A method of crosslinking polysaccharides by using photolabile protecting groups
CZ306662B6 (en) 2015-06-26 2017-04-26 Contipro A.S. Sulphated polysaccharides derivatives, the method of their preparation, the method of their modification and the use
EP3108874A1 (en) * 2015-06-26 2016-12-28 TRB Chemedica AG Ophthalmologic pharmaceutical composition
CZ308106B6 (en) 2016-06-27 2020-01-08 Contipro A.S. Unsaturated derivatives of polysaccharides, preparing and using them
CZ307158B6 (en) 2016-12-23 2018-02-07 Contipro A.S. An ophthalmic preparation
US11197841B2 (en) 2019-07-23 2021-12-14 Johnson & Johnson Surgical Vision, Inc. Compositions and methods for treating the eye
JP7374986B2 (en) 2018-07-27 2023-11-07 ジョンソン・アンド・ジョンソン・サージカル・ビジョン・インコーポレイテッド Compositions and methods for treating the eye
US10966948B2 (en) 2019-07-23 2021-04-06 Johnson & Johnson Surgical Vision, Inc. Compositions and methods for treating the eye
US11969454B2 (en) 2019-11-19 2024-04-30 Johnson & Johnson Surgical Vision, Inc. Compositions and methods for treating the eye

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101657194A (en) * 2007-03-05 2010-02-24 Indus生物技术私人有限公司 The pharmaceutical composition and the method thereof that comprise trigonelline and 4-hydroxyisoleucine
CN101687002A (en) * 2007-04-13 2010-03-31 V-生物技术控股有限责任公司 Extract of trigonella foenum-graecum

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101657194A (en) * 2007-03-05 2010-02-24 Indus生物技术私人有限公司 The pharmaceutical composition and the method thereof that comprise trigonelline and 4-hydroxyisoleucine
CN101687002A (en) * 2007-04-13 2010-03-31 V-生物技术控股有限责任公司 Extract of trigonella foenum-graecum

Also Published As

Publication number Publication date
WO2013171764A2 (en) 2013-11-21

Similar Documents

Publication Publication Date Title
WO2013171764A3 (en) Ophthalmic formulations
HK1205928A1 (en) Ocular drug delivery system
MY171920A (en) Prevention and treatment of ocular conditions
EP2838470A4 (en) Delivery system for ocular implant
ZA201301155B (en) Ophthalmic drug delivery
MY177912A (en) Vegf neutralizing prodrugs for the treatment of ocular conditions
HK1210968A1 (en) Compositions and treatment for eye diseases and disorders
EP2872118A4 (en) Hydrogel fragrance capsule, formulations and process for preparing the same
CL2013002134A1 (en) Topical administration ophthalmic pharmaceutical composition comprising an androgen; and method to treat an eye condition resulting from an androgen deficiency.
EP2849770A4 (en) Pharmaceutical compositions for the delivery of substantially water-insoluble drugs
IT1404931B1 (en) OPHTHALMIC COMPOSITIONS FOR THE ADMINISTRATION OF LIPO-SOLUBLE ACTIVE PRINCIPLES.
WO2012119070A3 (en) Silicone-based ophthalmic formulations
HK1205462A1 (en) Pharmaceutical preparation containing an antivirally active dihydroquinazoline derivative
EP3052095A4 (en) Epinephrine-based ophthalmic compositions for intraocular administration and methods for fabricating thereof
WO2012106427A3 (en) Methods for treating diabetic foot ulcers
IL227352A0 (en) Ocular drug delivery system
HK1204992A1 (en) Topical ophthalmological pharmaceutical composition containing sunitinib
WO2014076712A3 (en) Lurasidone hydrochloride solid dispersion
MX2016015211A (en) Topical formulations and uses thereof.
EP2846747A4 (en) Light degradable drug delivery system for ocular therapy
HK1208188A1 (en) Formulations for the delivery of active ingredients
MX2015007731A (en) Pharmaceutical formulation comprising ciclesonide.
EP2785335B8 (en) Methods and pharmaceutical compositions for the treatment of darier disease
HK1204289A1 (en) Topical ophthalmological pharmaceutical composition containing cediranib
HK1206254A1 (en) Stable liposomal formulations for ocular drug delivery

Legal Events

Date Code Title Description
122 Ep: pct application non-entry in european phase

Ref document number: 13790546

Country of ref document: EP

Kind code of ref document: A2